BACKGROUND: Chronic myeloid leukemia (CML) is one of the indolent myeloproliferative neoplasms. It is characterized by the presence of the Philadelphia chromosome, a translocation between chromosomes 9 and 22 or BCR-ABL1 gene.
Introduction
C hronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm, characterized by t(9:22) translocation, which produces the BCR-ABL fusion gene which codes for an abnormal tyrosine kinase responsible for the malignant proliferation of myeloid cells. [1] CML used to be classified into three disease phases: chronic phase (CP), accelerated phase, and blast phase (BP) with diagnosis most commonly made during the CP. [2] CML can be easily diagnosed in an appropriate clinical setting with view of typical hematology and morphology findings. It could be diagnosed in the presence of splenomegaly, leukocytosis (with predominance of neutrophils and myelocytes), and hypercellular bone marrow (BM), which is mainly granulocytic or granulocytic and megakaryocytic hyperplasia. [3] The Philadelphia (Ph) chromosome is usually present in 100% of metaphases, often as the sole abnormality; 10%-15% of patients have additional chromosomal abnormalities. A few CML patients may not demonstrate Ph chromosome yet have clinical course and morphological features just like typical CML. [4] There are several prognostic scoring systems for patients with CML, from which the Sokal et al., Hasford et al.,(or Euro) and European Treatment and Outcome Study (EUTOS) scores are the most popular. [5, 6] Cytogenetic and molecular analyses by fluorescent in situ hybridization (FISH) and polymerase chain reaction (PCR), respectively, have become mandatory for diagnostic evaluation and monitoring response to tyrosine kinase inhibitors (TKIs). [7] PCR is either qualitative used as a diagnostic tool, while quantitative reverse transcriptase-PCR (RT-PCR) is highly sensitive for detection of Minimal Residual Disease MRD. [8] The optimal and desired response to TKIs is defined according to: 1. National Comprehensive Cancer Network recommendations: [9] 2. European Leukemia Net (ELN) recommendations: [10] • 3 months: Ph+≤35% and/or BCR-ABL ≤10% • 6 months: Ph + 0%, and/or BCR-ABL <1% • 12 months: BCR-ABL≤0.1%.
A good correlation exists between BM cytogenetics and transcript levels in peripheral blood, with a BCR-ABL1 ≤10% equivalent to a major cytogenetic response and a BCR-ABL1 ≤1% equivalent to a CCyR. [11] The aim of this study is to assess CML patients at Nanakaly hospital; evaluating their main clinical presentation, the laboratory profile, the prognostic risk group distribution according to Sokal and EUTOS scores, and molecular response to TKIs.
Patients and Methods
The study designed as a prospective and retrospective observational study. It is conducted at Nanakaly The Sokal score and EUTOS score were calculated using previously published formulae (below) which was used to classify the patients into different risk groups.
Sokal score = Exp [0.0116× (age in years-43.4) +0.0345× (spleen size-7.51) +0.188 9 ([platelet count ⁄ 700]2-0.563) +0.0887× (blast cell counts-2.10)], where Exp is the exponential function. [5] EUTOS score = (7× basophils) + (4× spleen size). [6] Molecular responses are quantified by measuring the reduction in BCR-ABL transcript levels on an agreed-upon international scale (IS): [12] • MMR = BCR-ABL1 ≤0.1% IS, • Complete molecular response (CMR) recently labeled "deep molecular response" which includes MR, 4 MR 4.5 and MR 5 (≤0.01% IS, ≤0.0032% IS, and ≤0.001IS respectively).
Statistical analysis
Data were recorded on a specially designed questionnaire, collected and entered in the computer and then analyzed using Statistical Package for Social Sciences (SPSS (Armonk, NY: IBM Corp, USA)) version 22 and the results compared between patients with different variables, with a statistical significance level of P ≤ 0.05.
The results presented as rates, ratios, frequencies, and percentages in tables and figures and analyzed using t-test, Chi-square, and regression tests.
Results
This study recruited 76 patients; with a mean (± SD) age of 43.3 (SD 15.6) years. Age range was 12-80 at diagnosis; median age was 45 years, with the majority 70% of the patients being between 30 and 59 years. Data are shown in Figure 1 . There was 40 males (52.6%) and 36 females (47.4%); the male to female ratio was (1:0.9). Most of the patients 97% were in CP.
The main clinical presentations were abdominal fullness, pallor, weight loss, and fatigue (66%, 58%, 54%, and 45%, respectively); splenomegaly was the predominant (95%) physical sign with a mean longitudinal axis (± SD) of 17.86 (±4.6) cm; 26% among them had massive (>10 cm below costal margin) splenomegaly. Only 4% of patients were asymptomatic. Other parameters at diagnosis are shown in Table 1 .
The main hematology laboratory findings are shown in Table 2 . Hemoglobin (Hb%) mean (±SD) value was 10.4 ± 2 (range 5-15.3 g/dl); 90% of male and 72% of female recruited patients were anemic at presentation [ Figure 2 ]; White blood cell (WBC) count mean (±SD) was 178.5 ± 112 (range 24-580 × 10 9 /l). In 82% of patients, WBC count was >100 × 10 9 /l [ Figure 3 ]. The mean (±SD) of platelet count was 412.3 ± 282.5 (range 70-1850 × 10 9 /l); 38% of enrolled patients had thrombocytosis and 4% of them had thrombocytopenia [ Figure 4 ].
All patients had BM examination and the main finding was granulocyte and megakaryocytic hyperplasia (95% and 55%, respectively). The BM blast cell percentage at the time of diagnosis ranged from 0 to 7 with a mean value of 2.5 ± 1.5. Table 3 ].
Comparison of clinical and laboratory characteristics of patients who did versus did not achieve MMR/CMR revealed some significant differences [ Table 4 and Figure 5 ]; age, gender, spleen size, initial total WBC count, erythrocyte sedimentation rate, and LDH were not significant predictive factors to achieve MMR/CMR, while Hb level, promyelocyte, and myelocyte count were significantly different among both groups with P = 0.02, 0.006, and 0.03, respectively.
Considering the association between molecular response and the type of TKI used, CML patients were divided into 3 groups [ Table 3 ]. Patients who were treated with frontline Imatinib (68 patients) were subdivided into two groups:
(1) patients who were continued on Imatinib (30 patients), and (2) patients who switched from Imatinib to Nilotinib (38 patients). Patients received Nilotinib as frontline comprises the third group (8 patients). There was no significant difference among those who achieved MMR/CMR and the type of TKI (P = 0.68) [ Table 3 ].
The frequency of low-risk patients according to Sokal and EUTOS scores [Figures 6 and 7] was significantly
higher (P = 0.02 and 0.001, respectively) among those achieved MMR/CMR. 
Discussion
CML presents itself at a younger age than in western countries. [13] In the current study, the median age of patients is 45 years; it is almost the same as registered in Baghdad (44 years) [14] and quite close to the neighbor countries like Iran and Turkey (41, 46 respectively); [15, 16] this disparity in the main age group is probably related to the genetic background.
The majority of enrolled patients was symptomatic; only 4% of them were asymptomatic in comparison to western data where approximately 40% of patients are asymptomatic and diagnosed on the basis of abnormal counts. [17] Faderl et al. [18] reported that 50% of CML cases has been detected by routine tests. Most of the patients (90% male, 72% female) were anemic at presentation; the majority 82% of them had marked leukocytosis of >100 × 10 9 /l. Splenomegaly was seen in 95% of patients with about a quarter of them had massive splenomegaly; while data from the EUTOS population-based registry [19] revealed no palpable spleen in 53.5% of the patients, and a big spleen (⩾10 cm below costal margin) was reported in only 15.2%. On the other hand, our finding was exactly similar to those reported in Pakistan; [20] this disproportional finding probably relates to a better medical care with a current medical practice enhancing an earlier diagnosis in developed countries and to a lower degree of orientation and awareness of our population about such a medical problems.
The risk group distribution of the studied patients shows predominance of low and intermediate Sokal risk groups (47%, 45% respectively); this is in accordance with other studies. In the study by Hasford et al., [6] 39%, 37%, and 24% of cases had low-, intermediate-, and high-risk Sokal scores, respectively. A Japanese study also had lower proportion of cases 18.6% of high Sokal score. [21] Regarding EUTOS score, the low score was predominant at 66%, but the high score (34%) in the current study was more frequent than their counterpart in the USA, Europe, and Japan 10%-11%. [4, 6, 21] This could be explained by late presentation of patients; second, due to high basophil count with a mean (±SD) of 4.26 ± 2.65; and third, the majority of patients had splenomegaly (the last two factors are the main components of EUTOS score equation as mentioned earlier). The EUTOS score was reported to have superior prognostic value than Sokal score in evaluating patients with CML on Imatinib treatment. [6] One of the aims of CML treatment is to avoid disease progression from CP to BP. [22] Because CML patients who obtained MMR had a significantly lower risk of disease progression, MMR at 18 months has been an important surrogate biomarker for the long-term outcome prediction of Imatinib treatment according to the ELN recommendation guidelines. [22] About 70% of patients in the current study achieved MMR, which is comparable to some extent to other studies from PETHEMA (Spain), German Study Group IV and GIMEMA (Italy) studies 63%-85%, [23] [24] [25] and much higher than International Randomized Study of Interferon and STI571 (IRIS study) and a Turkish study (39% and 49% respectively). [26, 27] Fortunately, nowadays, with availability of RT-PCR, we could apply newly upgraded ELN guideline for treating our CML patients. [8] In the current study, there was a statistically significant difference in hemoglobin level, promyelocyte, and myelocyte count between those who achieved MMR/CMR versus those who did not, while other variables such as age, gender, initial total WBC count, spleen size, and LDH were not significantly correlated.
There was a significant association as well between molecular response and risk group scores: 80% of those with low EUTOS score and 86% low Sokal scores achieved MMR/CMR [ Figures 6 and 7 ].
There was no statistically significant correlation between the type of TKIs used and rate of MMR/CMR (P = 0.68), this was not comparable with ENESTnd study (Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients) that showed a statistically significant higher rates of MMR was achieved for Nilotinib compared with the Imatinib group (44 and 43% vs. 22%, P < 0.001). [28] This discordance is mostly linked to the smaller number of our patients whom treated with Nilotinib as a frontline. This attributed to: (1) the policy of Nanakalys Hospital (Nilotinib was used for the first time at Nanakaly hospital in 2012) for using Nilotinib (Tasigna®) mainly as a second line for patients with Imatinib (Gleevec®) resistant and failure, and (2) irregular availability of Nilotinib, makes its prescription to be limited.
Interestingly, two-thirds of the patients who switched from Imatinib to Nilotinib achieved MMR/CMR. This figure is much higher than the US and China, 28% and 39%, respectively. [29, 30] 
Conclusion
In the current study, CML patients were at a younger age of onset, were in the CP, had more splenomegaly, more leukocytosis, and more high EUTOS score. The majority of patients achieved MMR with frontline Imatinib or Nilotinib and those who switched from Imatinib to Nilotinib as well. With current practice of RT-PCR monitoring for molecular responses and hopefully provision of regular supply of TKIs to our CML patients, the ELN recommendations could be applied precisely and patients who are not responding optimally to treatment can be identified and managed properly to minimize the risk for disease progression.
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